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Introduction
Acute lymphoblastic leukemia (ALL) is the most frequent 
malignant neoplasm in childhood and accounts for ap-
proximately 30% of  pediatric cancers (1). Although cyto-
toxic drug protocols have led to a remarkable improvement 
in the prognosis of  this disease, a subset of  children with 
ALL still relapse.
The clinical suspicion of  recurrence may at times be dif-
ficult to define, since many other conditions (such as infec-
tion and drugs) induce similar symptoms, including cy-
topenia, hepatosplenomegaly, and lymphoadenopathy.
Positron emission tomography (PET) with 2-18F-2-
deoxy-D-glucose (FDG) has been reported as being a reli-
able, noninvasive, diagnostic imaging tool for various kinds 
of  malignancies, including lung cancers (2), colorectal can-
cer (3), head and neck epithelial neoplasia (4) , thyroid car-
cinoma (5), and breast cancer (6). This technique is also 
useful in detecting extramedullary neoplastic infiltrates in 
an acute myeloid leukemia patient (7). As regards the role 
of  FDG-PET in lymphoid malignancies, many studies have 
been carried out on both Hodgkin lymphoma (HL) and 
non-Hodgkin lymphoma (NHL) patients (8, 9). However, 
data concerning lymphoid leukemia are, at present, limited 
to reports describing the detection of  ALL involvement of  
tissues other than lymph nodes in adult patients (10-12). 
FDG-PET is also emerging in pediatric oncology as both 
an integral part of  the staging process and an essential tool 
in assessing therapy response (13, 14).
Fluorodeoxyglucose positron emission tomography/
computed tomography (FDG-PET/CT) is a hybrid diag-
nostic technique that allows a combination of  both ana-
tomical and biological coregistered images to be acquired 
in the same session. The CT scan increases PET topo-
graphic accuracy in the detection of  neoplastic lesions.
We report a case of  an ALL off-therapy patient, in which 
FDG-PET/CT was used to define more clearly the cause of 
lymphadenopathy. A subsequent histopathological exam 
revealed that this lymphadenopathy was due to disease re-
currence. FDG-PET/CT was then used to assess the effect 
of  the second-line therapy.
Case report
A 4-year-old boy was diagnosed with pre-B acute lym-
phoblastic leukemia (ALL). He was enrolled and treated 
according to the AIEOP (Italian Association of  Pediatric 
Hematology and Oncology)-BFM (Berlin-Frankfurt-
Munich) ALL 2000 Study Protocol (protocol for the diag-
nosis and treatment of  acute lymphoblastic leukemia in 
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pediatric patients). He was diagnosed disease-free and was 
off-therapy two years later. 
Five years later, the patient was re-evaluated for isolated 
submandibular lymphadenopathy. The physical exam 
showed generally good physical condition, with no fever, a 
slight (1/6) heart murmur, no respiratory abnormalities, 
and no hepatosplenomegaly. In the left submandibular re-
gion was a distinct mobile, hard, painful mass measuring 2 
cm in diameter, with no signs of  inflammation in the over-
lying skin. The pharynx and oral cavity were normal. The 
peripheral blood smear and hematologic indices were nor-
mal, as were hepatic and renal function. Furthermore, 
there was no serological evidence of  a recent infection 
(Toxoplasma, Bartonella, Epstein-Barr virus, and cy-
tomegalovirus were IgG-negative). A tuberculin skin test 
was negative. Empirical antibiotic and anti-inflammatory 
therapy with claritromycin and ketoprofene was given 
without any results. 
One week later, ultrasonography (US) of  the neck high-
lighted the presence of  a hypoechoic lymph node in the left 
submandibular region measuring 2.34 cm x 1.89 cm. This 
node had an heterogeneous appearance, with well-confined 
edges and demonstrated early signs of  internal liquefactive 
necrosis. The right lateral cervical lymph nodes were nor-
mal in shape and size. The left-sided nodes appeared en-
larged but displayed normal US features. The antibiotic 
therapy was changed to rifampicin. After one week, no no-
table changes could be seen by US. A chest radiograph and 
an abdominal US performed at this time were both 
normal. 
Even though the US images showed no suspicion for a 
recurrence of  the primary disease, the poor response to 
antibiotic therapy and the absence of  other causes of  the 
lymphadenopathy led to a total body FDG-PET/CT study 
in order to metabolically characterize the lymph nodes. 
This study was performed using a Discovery-STE PET/CT 
system (GE Medical Systems, Milwaukee, WI), 60 minutes 
after intravenous injection of  18F-FDG (167 MBq). At the 
time of  the tracer injection, the patient had fasted for over 
six hours, and his glucose blood level was 94 mg/dl. The 
data was acquired in 3D mode, with attenuation correction 
calculated by coregistered CT images. 
The PET study showed the presence of  heterogeneous 
uptake on the bilateral lateral cervical and bilateral supra-
clavicular lymph nodes, suggesting the presence of  disease 
with high metabolic activity in these sites (Fig. 1). A com-
plete left submandibular lymph-node excision and a bone-
marrow aspiration were done. The histopathological exam 
revealed a total alteration of  the normal structure of  the 
lymph node, with a massive neoplastic invasion by small 
lymphoid blasts. Immunophenotypic analysis showed that 
these cells were positive for CD10, CD19, TdT, and CD38. 
The bone-marrow aspiration showed the presence of  5% 
pre-B blasts.
In light of  data from the lymph node biopsy, bone-
marrow aspirate, and PET-CT scan, the patient was diag-
nosis with a combined (bone marrow and multiple lymph 
nodes) recurrence of  ALL. He was treated according to the 
AIEOP LLA REC2003 protocol (protocol to treat relapsing 
Philadelphia-chromosome-negative ALL).
After completing second-line therapy, FDG PET/CT 
was repeated to restage the lymph-node disease. No patho-
logical uptake was observed in the previously mentioned 
sites, suggesting a complete disease response to the treat-
ment (Fig. 2). Moreover, the bone-marrow aspirate per-
formed on the same day showed complete disease 
remission.
As an allogenic hematopoietic stem-cell transplantation 
(HSCT) was indicated, a mismatched unrelated allograft 
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Figure 1. Ultrasonography of the neck shows (A) the pres-
ence of a hypoechoic lymph node with a heterogeneous 
appearance in the left submandibular region, with well-
confined edges and early signs of internal liquefactive ne-
crosis, and B) right lateral cervical lymph nodes that are 
normal in shape and size.
was performed. One year following this transplant, the pa-
tient is alive, disease-free, and in good condition (Fig. 3). 
Discussion
Common sites of  primary involvement or recurrence of  
ALL include the testicles (2%) (15) and the central nervous 
system (CNS) (5%-11%) (16). However, other organs such 
as ovaries, breast, eye, skin, and lymph nodes have also 
been reported as a possible target of  the disease (17).
18F-FDG-PET is an advanced imaging tool for diagno-
sis, staging, and restaging of  cancer, identifying the in-
creased glycolytic activity in malignant cells. It is possible to 
image the entire body in a single session, increasing the 
opportunity of  finding unsuspected disease sites (18).
The most remarkable suggestion arising from our case is 
the higher sensitivity of  this imaging technique in the de-
tection of  ALL lymph-node involvement as compared to 
other techniques such as US. As regards our patient, the 
FDG-PET/CT scan correctly identified pathological up-
take both in regions that were falsely negative for leukemic 
cell infiltrates on US (for example, right lateral cervical re-
gion) and those that are quite difficult to study due to their 
anatomical location, such as the supraclavicular region. 
Furthermore, while the US images of  the enlarged lymph 
node suggested an infection, the FDG-PET/CT scan raised 
a suspicion for recurrence that was later confirmed by the 
histopathological exam. This suggests that FDG-PET/CT 
also provides a better specificity than US.
However, FDG is not a cancer-specific agent, and false-
positive findings have been reported. Infectious diseases 
(mycobacterial, fungal, and bacterial), sarcoidosis, radiation 
pneumonitis, and postoperative surgical conditions are as-
sociated with intense uptake of  FDG on PET scans (19). 
On the other hand, as reported in literature, limited sen-
sitivity related to the size of  metastatic deposits can be a 
particular problem with FDG-PET (20). Yet it has also been 
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Figure 2. Three adjacent, axial, 
T2-weighted MR images show 
retraction of the trapezius mus-
cles from the spinous processes 
with surrounding hematoma. 
There are areas of nodularity 
within the fluid collection that 
represent torn fragments of 
muscle.
suggested that the detection of  subclinically metastatic 
nodes in FDG-PET depends not only on the nodal size but 
also (to a greater degree) on the intranodal tumor burden 
(21).
Nevertheless, our case suggests some promising features 
of  FDG-PET/CT scan in ALL, such as the opportunity to 
further guide diagnostic interventions and thus focus on 
probable sites of  disease recurrence. FDG-PET/CT also 
has the advantage of  staging tissues other than blood with 
just a single exam. Endo et al. reported a rare case of  an 
adult patient with ALL who suffered a relapse in the bone 
marrow of  the extremities following allogeneic peripheral 
blood-stem-cell transplantation (22). These authors sug-
gested that in cases of  disease recurrence in unusual sites, 
evaluation by MRI and FDG-PET may be of  value in de-
tecting these relapses (22). Moreover, whole-body FDG-
PET/CT during the course of  the therapy might be useful 
in assessing the chemotherapeutic effects on identified le-
sions. This type of  effect is accepted as one of  the most 
important prognostic factors in ALL (23, 24). 
The findings in our patient are consistent with those from 
previous reports. However, our case demonstrated some 
original features, such as the opportunity to intentionally 
detect leukemic cell infiltrates in lymph nodes, and the ap-
plication of  FDG-PET/CT in pediatric ALL patients. 
However, the limits of  this diagnostic tool must be also 
considered. The main limits of  FDG-PET/CT scan are the 
exposure of  the patient to an estimated radiation dose of  
approximately 25 mSv (25), which can be a significant 
problem in pediatric patients (26, 27). The present avail-
ability and costs of  the FDG-PET/CT are other limita-
tions. It is clearly evident that more studies are needed to 
assess a possible role of  FDG-PET/CT in the management 
of  ALL patients. If  the suggestions arising from this report 
are confirmed, FDG-PET/CT may be included in future 
clinical practice for disease staging, evaluating the response 
to the chemotherapy in identified lesions and in the restag-
ing for recurrence of  extramedullary disease.
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